GlassScriptPhysician profile
Mara M Morabito
NPI 1598914277
$3,775.57
in general payments reported to CMS, 2019-2025
23 companies · $411 in 2025
The $411 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $381 · 2022: $1,108 · 2023: $1,101 · 2024: $775 · 2025: $411.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,286.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,286.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $834.76 | 2021-2025 | Proclaim, Eterna |
| Abbvie INC. | $609.93 | 2021-2025 | |
| Medtronic, INC. | $597.38 | 2021-2025 | Inceptiv, Intellis Adaptivestim |
| Boston Scientific Corporation | $449.72 | 2023-2025 | Wavewriter Alpha Prime 16 |
| Collegium Pharmaceutical, INC. | $334.53 | 2022-2024 | Xtampza, Belbuca |
| Teva Pharmaceuticals USA, INC. | $203.39 | 2022-2023 | Ajovy, Austedo Xr, Ajovy |
| Biohaven Pharmaceutical Holding Company LTD. | $102.01 | 2022 | |
| Pfizer INC. | $96.24 | 2023-2024 | |
| Vertex Pharmaceuticals Incorporated | $89.04 | 2024-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $80.91 | 2022-2023 | Relistor |
| Lilly USA, LLC | $75.25 | 2022-2025 | Emgality, Reyvow, Zepbound |
| Biohaven Pharmaceuticals, INC. | $69.70 | 2021 | |
| Scilex Pharmaceuticals INC. | $36.88 | 2022-2024 | |
| Relievant Medsystems, INC. | $32.24 | 2022 | |
| Amneal Pharmaceuticals LLC | $25.65 | 2023 | Lyvispah |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merz Pharmaceuticals, LLC | $21.32 | 2024 | Xeomin |
| Xeris Pharmaceuticals, INC. | $19.78 | 2024 | Keveyis |
| Spr Therapeutics, INC | $19.00 | 2023-2024 | Sprint Pns System |
| Kowa Pharmaceuticals America, INC. | $18.34 | 2023 | Seglentis |
| Fidia Pharma USA INC. | $16.74 | 2022 | |
| Stimwave Technologies Incorporated | $14.88 | 2022 | |
| International Rehabilitative Sciences, INC | $14.86 | 2023 | Rs 4i Plus Sequential Stimulator |
| Lundbeck LLC | $13.02 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mara Morabito listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.